BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25557847)

  • 1. Elevation of serum KL-6 in patients with psoriasis treated with anti-tumour necrosis factor-α therapy.
    Higashi Y; Tada K; Shimokawa M; Kawai K; Kanekura T
    Clin Exp Dermatol; 2016 Jan; 41(1):88-90. PubMed ID: 25557847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level.
    Chijiwa C; Takeoka S; Kamata M; Uchida H; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    Br J Dermatol; 2018 Dec; 179(6):1396-1397. PubMed ID: 29985537
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis.
    Hayashi M; Yanaba K; Umezawa Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1063-1066. PubMed ID: 28370220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
    Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs.
    Harigai M; Takamura A; Atsumi T; Dohi M; Hirata S; Kameda H; Nagasawa H; Seto Y; Koike T; Miyasaka N
    Mod Rheumatol; 2013 Mar; 23(2):284-96. PubMed ID: 22588312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of colon cancer by increased serum level of Krebs von den Lungen-6 in a patient with dermatomyositis-associated interstitial pneumonia.
    Fukuhara N; Tanino Y; Sato S; Fukuhara A; Uematsu M; Nikaido T; Misa K; Sato Y; Saito J; Wang X; Munakata M
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):265-70. PubMed ID: 26422573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis.
    Mabuchi T; Yamaoka H; Kawai M; Ota T; Ozawa A
    J Dermatol; 2014 Dec; 41(12):1136-7. PubMed ID: 25388751
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
    Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
    Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab.
    Kurita M; Kikuchi S; Umezawa Y; Asahina A; Nakagawa H; Yanaba K
    J Dermatol; 2019 Apr; 46(4):e115-e116. PubMed ID: 30204267
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of anti-interleukin-17 biologics on Krebs von den Lungen-6 level in patients with psoriasis.
    Hara H; Miyagawa H; Araya J; Minagawa S; Numata T; Umezawa Y; Asahina A; Nakagawa H; Kuwano K
    J Dermatol; 2021 Jun; 48(6):886-893. PubMed ID: 33860559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Krebs von den Lungen-6 levels in psoriatic patients under treatment with biologics.
    Iwata H; Haga N; Sugai T; Fujita Y
    J Dermatol; 2021 Mar; 48(3):376-379. PubMed ID: 33146900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
    Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in Serum KL-6 Level during Biologic Treatment for Psoriasis.
    Hoashi T; Miyazaki S; Ozaki S; Ichiyama S; Ito M; Kanda N; Saeki H
    J Nippon Med Sch; 2023; 90(2):194-201. PubMed ID: 37258257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Value of Biomarkers as Predictors of Outcome in Patients with Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia.
    Lee YS; Kim HC; Lee BY; Lee CK; Kim MY; Jang SJ; Lee HS; Moon J; Colby TV; Kim DS
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):216-223. PubMed ID: 27758986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
    Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
    Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
    Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
    Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.
    Takamura A; Hirata S; Nagasawa H; Kameda H; Seto Y; Atsumi T; Dohi M; Koike T; Miyasaka N; Harigai M
    Mod Rheumatol; 2013 Mar; 23(2):297-303. PubMed ID: 22572888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.